Consistent with the in-vitro results, induction of MCL1 knockdown in tumor xenografts established from melanoma cells expressing doxycycline-inducible shRNA against MCL1 resulted in decrease in mTORC1 activity (Fig. 3I and Supplementary Fig. 4A), which was concomitant with decline in respiration (Fig. 3J and Supplementary Fig. 4B) and decline in ATP production rather than utilization (Fig. 3K and Supplementary Fig. 4C-E). This evidence concerns the gene MCL1 and melanoma.